Opportunity Information: Apply for PAR 08 147
Apply for PAR 08 147
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Quick Trials for Imaging and Image Guided Interventions Exploratory Grants (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.398 Cancer Research Manpower 93.399 Cancer Control.
- This funding opportunity was created on Dec 31, 2008 and posted on Dec 31, 2008.
- Applicants must submit their applications by Apr 11, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education Public and State controlled institutions of higher education State governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Quick Trials for Imaging and Image Guided Interventions Exploratory Grants (R21) opportunity (PAR-08-147) was a National Institutes of Health (NIH) funding announcement designed to speed up early clinical testing of new or improved cancer-related imaging and image-guided intervention approaches. The central aim was to help investigators move promising imaging discoveries into clinical practice faster by providing support for small, early-stage studies that can quickly generate human data on feasibility, safety, and signals of effectiveness. Rather than funding large definitive trials, this FOA emphasized "quick" exploratory clinical work that can determine whether an imaging agent, imaging method, or image-guided therapy tool is ready for more extensive validation.
The scope of supported projects focused on clinical trials and closely related clinical studies that evaluate imaging agents and imaging technologies in people. This included preliminary (early) assessment of the safety and efficacy of imaging agents, along with evaluation of imaging systems and the technical pipeline around them, such as image processing methods, quantitative tools, contrast kinetic modeling, and 3D reconstruction approaches. It also included image-guided therapy and broader image-guided intervention (IGI) techniques, where imaging is used to plan, target, guide, or monitor an intervention. The FOA also allowed for patient monitoring studies and laboratory studies connected to patient-based work, as long as they supported the overall goal of rapid clinical translation and early performance assessment.
In terms of trial stage, the announcement was intended to support pilot cancer clinical trials, particularly Phase I and Phase II efforts, where the main goals are typically to establish safety, optimize use parameters, and look for early evidence that the imaging approach provides clinically meaningful information. The expectation was that successful R21-funded studies would produce enough data to justify and shape larger follow-on studies. If early results were encouraging, investigators were expected to pursue broader validation through standard NIH mechanisms such as an R01, or through larger clinical trial infrastructures like Specialized Programs of Research Excellence (SPOREs), NCI-designated Cancer Centers, and/or Cooperative Groups. In other words, this R21 was positioned as a bridge between bench or prototype development and the larger, resource-intensive trials needed for clinical adoption.
Administratively, this was a discretionary grant opportunity using the NIH R21 exploratory/developmental grant mechanism, which is generally used for early, high-potential projects where preliminary data may be limited but the concept is strong and time-sensitive. The activity area was health, and it mapped to multiple cancer-related CFDA numbers spanning prevention, detection/diagnosis, treatment, biology, workforce, and cancer control, reflecting the broad relevance of imaging across the cancer research continuum. The opportunity did not require cost sharing or matching.
Eligibility was broad and included many organization types that commonly conduct biomedical research and clinical studies. Eligible applicants included private and public institutions of higher education (including state-controlled universities), state governments, small businesses, nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits other than universities), and for-profit organizations (other than small businesses). This wide eligibility was consistent with the translational nature of imaging research, where innovations can come from academic labs, medical centers, and industry developers working toward clinical testing.
Key dates show that the FOA was posted and created on December 31, 2008, with an original and final closing date of April 11, 2011, and it was archived on May 11, 2011. The listing shows an award ceiling of 0, which typically indicates that a specific per-award cap was not presented in that summary field (actual budget limits are usually governed by the R21 mechanism and the detailed FOA text). The sponsoring agency was NIH, and the full announcement was hosted on the NIH grants site under PAR-08-147. For access or linking issues, the NIH Office of Extramural Research (OER) webmaster contact information was provided.
Quick Trials for Imaging and Image Guided Interventions Exploratory Grants (R21) (PAR-08-147) - FAQs
What is PAR-08-147 (Quick Trials for Imaging and Image Guided Interventions Exploratory Grants - R21)?
PAR-08-147 was a National Institutes of Health (NIH) funding announcement for R21 exploratory/developmental grants. It was designed to speed up early clinical testing of new or improved cancer-related imaging approaches and image-guided intervention (IGI) methods by supporting small, early-stage studies in people.
What was the main goal of this grant opportunity?
The main goal was rapid clinical translation: helping investigators move promising imaging discoveries toward clinical practice faster by funding "quick" exploratory clinical work that could generate early human data on feasibility, safety, and signals of effectiveness.
Was this intended to fund large, definitive clinical trials?
No. This opportunity emphasized early, exploratory clinical studies rather than large, definitive trials. The intent was to determine whether an imaging agent, imaging method, or image-guided tool was ready for more extensive validation.
What types of projects were within scope?
The scope focused on clinical trials and closely related clinical studies evaluating imaging agents and imaging technologies in people. It also included image-guided therapy and other image-guided intervention techniques where imaging is used to plan, target, guide, or monitor an intervention.
Did the FOA support studies of imaging agents?
Yes. It supported preliminary (early) clinical assessments of imaging agents, including early evaluation of safety and efficacy in people.
Did the FOA support studies of imaging systems and related technical methods?
Yes. It included evaluation of imaging systems and the technical pipeline around them, such as image processing methods, quantitative tools, contrast kinetic modeling, and 3D reconstruction approaches, when tied to clinical evaluation in people.
What are "image-guided interventions" (IGI) in the context of this opportunity?
IGI referred to techniques where imaging is used to plan, target, guide, or monitor an intervention or therapy. The FOA supported early clinical testing of these imaging-enabled intervention approaches.
Were patient monitoring studies allowed?
Yes. Patient monitoring studies were allowed when they supported the overall goal of rapid clinical translation and early performance assessment of the imaging or image-guided approach.
Were laboratory studies allowed under this opportunity?
Laboratory studies could be included if they were connected to patient-based work and supported the overall aim of rapid clinical translation and early assessment in people.
What clinical trial phases were primarily targeted?
The announcement was intended to support pilot cancer clinical trials, particularly Phase I and Phase II efforts, where the goals commonly include establishing safety, optimizing use parameters, and looking for early evidence of clinically meaningful information.
What results were expected from an R21 funded under this FOA?
The expectation was that successful studies would generate enough early human data to justify and shape larger follow-on studies, helping determine readiness for broader validation.
What follow-on funding or pathways were anticipated if early results were encouraging?
If early results were promising, investigators were expected to pursue broader validation through standard NIH mechanisms such as an R01, or through larger clinical trial infrastructures such as SPOREs, NCI-designated Cancer Centers, and/or Cooperative Groups.
What grant mechanism was used?
This opportunity used the NIH R21 exploratory/developmental grant mechanism, which is typically used for early, high-potential projects where preliminary data may be limited but the concept is strong and time-sensitive.
Which federal agency sponsored this opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
What general activity area did this opportunity fall under?
The activity area was health, with an emphasis on cancer-related imaging and image-guided interventions.
How broad was the cancer relevance of the opportunity?
It mapped to multiple cancer-related CFDA areas spanning prevention, detection/diagnosis, treatment, biology, workforce, and cancer control, reflecting how imaging can contribute across the cancer research continuum.
Who was eligible to apply?
Eligibility was broad and included private and public institutions of higher education (including state-controlled universities), state governments, small businesses, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits other than universities), and for-profit organizations (other than small businesses).
Did applicants need to provide cost sharing or matching funds?
No. The opportunity did not require cost sharing or matching.
When was the funding announcement posted?
The FOA was posted and created on December 31, 2008.
What was the closing date for applications?
The listing shows an original and final closing date of April 11, 2011.
Is this funding opportunity still active?
No. The opportunity was archived on May 11, 2011.
What does it mean that the opportunity is archived?
Based on the provided information, "archived" indicates the FOA is no longer open and is maintained as a historical listing rather than an active funding opportunity.
Was there a stated maximum award amount (award ceiling)?
The listing shows an award ceiling of 0, which typically indicates that a specific per-award cap was not presented in that summary field. Budget limits are usually governed by the R21 mechanism and the detailed FOA text.
Where could applicants find the full announcement?
The full announcement was hosted on the NIH grants site under PAR-08-147.
Who was the contact for access or linking issues?
For access or linking issues, the NIH Office of Extramural Research (OER) webmaster contact information was provided in the listing.
Browse more opportunities from the same category: Health
Next opportunity: OVC FY 09 National Field Generated Training, Technical Assistance, and Demonstration Projects
Previous opportunity: OJJDP FY 09 National Mentoring Programs
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 08 147
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 08 147) also looked into and applied for these:
| Funding Opportunity |
|---|
| Data Coordinating Center for Autism and Other Developmental Disabilities Research and Epidemiologic Studies (U10) Apply for RFA DD 09 002 Funding Number: RFA DD 09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| NCI Transition Career Development Award to Promote Diversity (K22) Apply for PAR 09 069 Funding Number: PAR 09 069 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| TransACTION Prevention and Care Services for At Risk Mobile Populations Apply for 663 A 09 006 Funding Number: 663 A 09 006 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $40,000,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 09 070 Funding Number: PA 09 070 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 09 071 Funding Number: PA 09 071 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Chiropractic Demonstration Projects Apply for HRSA 09 108 Funding Number: HRSA 09 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Grants to States to Support Oral Health Workforce Activities Apply for HRSA 09 109 Funding Number: HRSA 09 109 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Clinical Interventions to Increase Organ Procurement Apply for HRSA 09 173 Funding Number: HRSA 09 173 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Part D Coordinated HIV Services and Access to Research for Women, Infant, Children and Youth Apply for HRSA 09 202 Funding Number: HRSA 09 202 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Licensure Portability Grant Program Apply for HRSA 09 196 Funding Number: HRSA 09 196 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Collaborative Study of Suicidality and Mental Health in the U.S. Army (U01) Apply for RFA MH 09 140 Funding Number: RFA MH 09 140 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Expansion for Enabling Services for Special Populations Apply for HRSA 09 190 Funding Number: HRSA 09 190 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| International Research in Infectious Diseases including AIDS (IRIDA) Program (R01) Apply for PAR 08 130 Funding Number: PAR 08 130 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Electronic Health Record Implementation Initiative Apply for HRSA 09 198 Funding Number: HRSA 09 198 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| The Bernard Osher Foundation/NCCAM CAM Practitioner Research Career Development Award (K01) Apply for PAR 09 072 Funding Number: PAR 09 072 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers (P50) and Exploratory Grants for Centers (P20) for Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEERs) Apply for RFA HG 09 003 Funding Number: RFA HG 09 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Small Grant Program for Conference Support (R13) Apply for PA 06 074 Funding Number: PA 06 074 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $50,000 |
| NINDS Clinical Trial Planning Grant (R34) Apply for PAR 06 460 Funding Number: PAR 06 460 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Telehealth Network Grant Program Apply for HRSA 09 194 Funding Number: HRSA 09 194 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Collaborative R34s for Pilot Studies of Innovative Treatments in Mental Disorders (Collaborative R34) Apply for PA 09 075 Funding Number: PA 09 075 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 147", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.